sur Pentixapharm Holding AG (ETR:PTP)
Pentixapharm's Financial Update and Strategic Focus for End of 2026
Pentixapharm Holding AG, a biotechnology firm, reported its Q3 and nine-month results for 2026, backed by the completion of a €20.4 million capital raise. This funding is expected to sustain operations until 2028. The company revised its full-year net loss forecast to €13 million, down from €21.6 million, due to cost deferrals and reduced amortization.
Key financial metrics show a cash reserve of €21.9 million by September 30, 2026, compared to €4.6 million in 2025. The company completed a rights offering in July 2026. Notably, Pentixapharm has confirmed the launch of its PANDA study by Q1 2027.
Recent amendments in financial statements, resulting from BaFin's concluded review, have prompted non-cash accounting adjustments impacting intangible assets and capital reserves.
The company's priorities include executing clinical programs and leveraging partnerships for future commercialization.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pentixapharm Holding AG